Pursuing Novel Ideas
Pioneering Innovative Therapies
Lipella's formation emanated from research conducted with funding from the National Institutes of Health (NIH) at academic medical centers as well as direct NIH funding to the company. Lipella's assets focus on drug delivery therapies for smooth muscle dysfunction.
Management Team
Michael
Chancellor, MD
Dr. Chancellor is internationally recognized as the leader in urinary
bladder treatment and research. Prior to joining Lipella, Dr.
Chancellor was Professor of Urology at the University of Pittsburgh
School of Medicine, and co-founder of Cook Myosite, originator of the
first approved U.S. human urologic stem cell clinical trial. Dr.
Chancellor has been principal investigator of over 75 additional
clinical trials including physician sponsored IND trials. He is the
recipient of over 25 NIH grants, and author of more than 300
peer-reviewed publications. He is consultant and advisory board member
to over a dozen companies including Pfizer, Merck, J&J, Lilly,
AstraZeneca, Allergan, Astellas, P&G and Indevus. Dr.
Chancellor
received his MD from the Medical College of Wisconsin, and completed
his residency and fellowship training at the University of Michigan and
Columbia University.
Jonathan
Kaufman, PhD
Prior to co-founding Lipella, Dr.Kaufman was Vice President and Chief
Science Officer of LaunchCyte LLC, a biotechnology corporate incubator.
At LaunchCyte, Dr. Kaufman was co-founder of Proteopure Inc. and Knopp
Neuroscience Inc.; served as the founding President of Crystalplex
Corp.; served on the Boards of Reaction Biology Corp., Crystalplex
Corp., and Immunetrics Inc.; and served as Secretary of Reaction
BiologyCorp. Prior to joining LaunchCyte, Dr. Kaufman served on the New
Technology Committee in the Chemical Manufacturing Division of Merck
& Co., and also served as a consultant to GlaxoSmithKline in
the
department of bioinformatics. Dr. Kaufman received his MBA in Finance
from the Wharton School, and his PhD in Biophysics from the University
of Pennsylvania School of Medicine.
John Park, J.D., LL.M.
Director Business Development
John Park has completed six major tech transfer/acquisition ($100 mil
plus) deals and numerous minor tech transfer transactions for over
twenty years. He was also a member of Tularik's Asia Representative
Team for the Amgen/Tularik $1.3 billion acquisition deal in 2004. John
has served as a corporate counsel for over ten pharmaceutical
companies in Asia and graduated from Boston University and Columbia
Law School.